Faricimab has met its primary endpoint in two global phase 3 studies, according to a press release.
YOSEMITE and RHINE investigated faricimab in patients with diabetic macular edema. In both studies, the drug was well tolerated, with no new safety signals, the release said.
When given every 8 weeks and at personalized dosing intervals up to 16 weeks, faricimab demonstrated noninferior visual acuity gains compared with aflibercept given every 8 weeks, according to the release.
Faricimab also met its secondary endpoint in more than half of patients in the personalized (Read more...)
Uncategorized